FSHDFacioscapulohumeral Muscular Dystrophy
FSHDFamily Studies and Human Development (degree program)
FSHDFlorida State Health Department
References in periodicals archive ?
We are very excited about working together with Facio in FSHD, a devastating disease with a high unmet medical need.
27 Facial weakness is often the earliest obvious clinical feature in FSHD that shows the facial muscle involvement thus leading to reduced facial expression.
To our knowledge, no therapeutic options have been suggested for patients with FSHD.
Our study identifies a range of cellular pathways involved in FSHD pathology.
The second interesting article [sup][2] is a research report of clinical and genetic analysis of FSHD in 178 individuals from 136 unrelated families in Chinese population.
a member of the Hutchinson Center's Human Biology Division, discovered that a rare variant of FSHD, called type 2, which accounts for about 5 percent of cases, is caused by two genetic mutations that together cause the production of muscle-damaging toxins responsible for causing symptoms of this progressive muscle disease.
Currently there is no therapy for FSHD and all the clinical trials based on increasing muscle mass or suppressing inflammatory reactions have been disappointing3.
patients with FSHD, more than one in a family, do others in your family
The application of neuromuscular electrical stimulation, as a surrogate for ST in patients with severe muscle weakness, has recently been reported to be well-tolerated and resulted in improved muscle strength in FSHD.
However, articles referring to populations with DM, OPMD, LGMD, FSHD, and other muscular dystrophies are also represented.
It has been demonstrated that diagnosis of Facioscapulohumeral muscular dystrophy (FSHD) could be distinguished from Duchenne muscular dystrophy based on the level of miRNAs-381 and miRNAs-382 expressions in FSHD patients (175).